Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06717490Recruiting
Magnesium and blood clot prevention in laparoscopic gynecologic surgery
This study looks at whether giving magnesium sulfate during surgery can help prevent blood clots in women having laparoscopic gynecologic procedures. It may offer an extra layer of protection for those already receiving standard clot-preventing medication.
Athens, AtticaAges 18 years+ - NCT04469517Recruiting
Study of low-oxygen factors in hereditary bleeding disorder
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT05203003Recruiting
Testing whether measurable cancer leftovers predict outcomes
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
ParisAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Aurora, ColoradoAges 18 years+ - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT07587723Recruiting
Real-world study of eltrombopag treatment in immune thrombocytopenia
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
BaselAges 18–100 - NCT06700395RecruitingPhase 1
Study of TQB2029 for multiple myeloma patients
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07586826RecruitingPhase 2
Romiplostim N01 plus ATRA for low platelets after cancer treatment
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
BeijingAges 18 years+ - NCT07594535RecruitingPhase 4
Testing a Blood Pressure Medicine for High Red Blood Cell Count
This study tests whether lisinopril, a common blood pressure medication, can help lower red blood cell counts in people who have elevated hemoglobin levels. Researchers want to see if this drug could offer a simpler treatment option for this condition.
Rochester, MinnesotaAges 18–80 - NCT07590986Recruiting
Finding immune markers in blood cell disorders
This research study looks for specific immune system clues in patients with myeloproliferative neoplasms—rare blood disorders where your bone marrow produces too many blood cells. By identifying these markers, researchers hope to better understand and eventually treat these conditions.
Brussels, WoluweAges 18 years+ - NCT07586813RecruitingPhase 2
Romiplostim N01 Plus ATRA for Low Platelets After Gut Cancer
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
BeijingAges 18 years+ - NCT07590804Recruiting
Plant-Based Diet Study for Blood Cell Cloning
This study tests whether eating more plant-based whole foods can help people with clonal hematopoiesis (a condition where blood cells grow from a single mutated cell). Researchers want to understand if dietary changes affect this condition and collect health information over time.
Basking Ridge, New JerseyAges 18 years+ - NCT07586735Recruiting
A new preparative regimen for stem cell transplant in older patients with severe aplastic anemia
This study tests a new combination of drugs to prepare older patients (40–60 years old) with severe aplastic anemia for a stem cell transplant from a half-matched donor. The goal is to make the transplant safer and more effective for this age group.
Beijing, Beijing MunicipalityAges 40–60 - NCT07587944Recruiting
Blood Markers to Predict AML Treatment Response
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Fuzhou, FujianAges 18 years+ - NCT07594496Enrolling by invitation
Cannabis Withdrawal in Blood Cancer Patients During Stem Cell Transplant
This study looks at whether patients with blood cancers who use cannabis experience withdrawal symptoms when hospitalized for stem cell transplant or CAR-T therapy (a type of immunotherapy). Understanding these symptoms could help doctors better support patients during treatment.
Scottsdale, ArizonaAges 18 years+ - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+ - NCT07587411Enrolling by invitation
Support program for children with leukemia and their families
This study tests a step-by-step support program designed to help children with leukemia and their parents or guardians cope better during cancer treatment. The program aims to reduce stress and improve quality of life for the whole family.
Peshawar, Khyber Pukhtoon KhwaAges 7–14 - NCT07587840RecruitingPhase 2
CAR-T Cell Therapy After Initial Treatment for Follicular Lymphoma
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
Beijing, Beijing MunicipalityAges 18–85 - NCT07588594Recruiting
Thiotepa-Based Stem Cell Transplant for Chronic Myelomonocytic Leukemia
This trial tests a chemotherapy regimen (thiotepa-containing preparation) combined with a stem cell transplant from a donor to treat chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if this approach helps patients with intermediate-to-high risk disease achieve remission.
BeijingAges 18 years+ - NCT07588568RecruitingPhase 2
Testing upadacitinib for EoE that doesn't respond to steroids
This study tests a pill called upadacitinib (a JAK inhibitor) in people with eosinophilic esophagitis (EoE) that hasn't improved with swallowed steroids. It aims to see if the drug can reduce inflammation and symptoms in the esophagus when added to your current steroid treatment.
Chapel Hill, North CarolinaAges 18–65 - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT06720324RecruitingPhase 1/Phase 2
CD7-targeted CAR-T therapy for relapsed blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a specific marker called CD7 on blood cancer cells. It is for people whose blood cancer has not responded to other treatments or has come back after treatment.
Wuhan, HubeiAges 3–75 - NCT06720870Recruiting
Siltuximab for Castleman's disease: a real-world study
This trial is looking back at the medical records of people with a rare condition called Castleman's disease to see how well the drug Siltuximab worked for them in everyday hospital care, not in a research setting. The goal is to learn more about how safe and effective the drug can be for patients in real life.
Bologna, BolognaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.